Patrick M. Caldwell
Profile
Patrick M.
Caldwell worked as Vice President-Finance & Controller at Protein Design Labs, Inc. and as Controller at Meta Software, Inc. He also briefly worked as Chief Accounting Officer at BioSpecifics Technologies Corp.
Mr. Caldwell obtained an undergraduate degree from San Jose State University.
Former positions of Patrick M. Caldwell
| Companies | Position | End |
|---|---|---|
| BIOSPECIFICS TECHNOLOGIES CORP. | Director of Finance/CFO | 05/01/2020 |
| Meta Software, Inc. | Comptroller/Controller/Auditor | 04/07/2019 |
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Director of Finance/CFO | - |
Training of Patrick M. Caldwell
| San Jose State University | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 3 |
|---|---|
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
BioSpecifics Technologies Corp.
 BioSpecifics Technologies Corp. Pharmaceuticals: MajorHealth Technology BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY. | Health Technology |
| Meta Software, Inc. | Finance |
- Stock Market
- Insiders
- Patrick M. Caldwell
